English
NONCLINICAL EVALUATION REPORT Submission type: New vaccine Sponsor: Pfizer Australia Pty Ltd Generic name: B NT 162b2 [mRNA] COVID - 19 vaccine Trade name: COMIRNATY Dose form and strength: Solution ; 500 μ g / mL (diluted to deliver 30 μ g/0.3 mL per injection) Vaccine Type : mRNA encapsulated in LNP Submission No: PM - 2020 - 05461 - 1 - 2 Tox file No: E20 - 375469 TRIM reference: D20 - 3908532 Date: 8 January 202 1 (revised 15 January 202 1 ) Page 4 “Almost similar microscopic lung inflammation was observed in both challenged control and immunised animals (macaques) after the peak of infection (Days 7/8)” Challenged with infection, (unvaccinated) control animals Almost similar microscopic lung inflammation Challenged with infection, immunized (vaccinated) animals Almost similar microscopic lung inflammation Page 4 “There are no distribution and degradation data on the S antigen-encoding mRNA.” A new therapy that uses an intra-cellular pathway to use intracellular ribosomes We know from page 45 the lipid nanoparticles are systemically distributed, But the spike protein that the RNA produces, distribution not tested No data on how long the spike protein persists Page 5 “Antibodies
Sign in with your free account to read, download EPUBs or listen.
Ebook · Pfizer Australia Nonclinical Evaluation of BNT162b2 [mRNA] COVID-19 vaccine (COMIRNATY) · Internet Archive
pfizer · covid19